Loading…
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes
Introduction COVID-19 cases are on surge; however, there is no efficient treatment or vaccine that can be used for its management. Numerous clinical trials are being reviewed for use of different drugs, biologics, and vaccines in COVID-19. A much empirical approach will be to repurpose existing drug...
Saved in:
Published in: | Pharmacological reports 2021-06, Vol.73 (3), p.736-749 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c446t-48497a8061629023898e67a71d17c2cbb5561fd8b28c3b898e2a5d5bb08bc3b83 |
---|---|
cites | cdi_FETCH-LOGICAL-c446t-48497a8061629023898e67a71d17c2cbb5561fd8b28c3b898e2a5d5bb08bc3b83 |
container_end_page | 749 |
container_issue | 3 |
container_start_page | 736 |
container_title | Pharmacological reports |
container_volume | 73 |
creator | Kaur, Harpinder Shekhar, Nishant Sharma, Saurabh Sarma, Phulen Prakash, Ajay Medhi, Bikash |
description | Introduction
COVID-19 cases are on surge; however, there is no efficient treatment or vaccine that can be used for its management. Numerous clinical trials are being reviewed for use of different drugs, biologics, and vaccines in COVID-19. A much empirical approach will be to repurpose existing drugs for which pharmacokinetic and safety data are available, because this will facilitate the process of drug development. The article discusses the evidence available for the use of Ivermectin, an anti-parasitic drug with antiviral properties, in COVID-19.
Methods
A rational review of the drugs was carried out utilizing their clinically significant attributes. A more thorough understanding was met by virtual embodiment of the drug structure and realizable viral targets using artificial intelligence (AI)-based and molecular dynamics (MD)-simulation-based study.
Conclusion
Certain studies have highlighted the significance of ivermectin in COVID-19; however, it requires evidences from more Randomised Controlled Trials (RCTs) and dose- response studies to support its use. In silico-based analysis of ivermectin’s molecular interaction specificity using AI and classical mechanics simulation-based methods indicates positive interaction of ivermectin with viral protein targets, which is leading for SARS-CoV 2 N-protein NTD (nucleocapsid protein N-terminal domain). |
doi_str_mv | 10.1007/s43440-020-00195-y |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7778723</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475093917</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-48497a8061629023898e67a71d17c2cbb5561fd8b28c3b898e2a5d5bb08bc3b83</originalsourceid><addsrcrecordid>eNp9UU2PEyEYJkbjdqt_wIPh6AXlawbwYGKqrk022Yt6JcAwXTYzUIHppv9eateNXjwQkueLl_cB4BXBbwnG4l3hjHOMMG0HE9Wh4xOwolQp1PWSPwUrIhhHhHB8AS5LucOYE8q65-CCMSaVoN0KHLYHn2fvaojQFGjgPlUfazATHPKyg2PKsGZv6txQmEa4ufmx_YSIeg9NhCGicowOZn8I_h7eh3oL3RRicM1v4gBdmvdLNTWkeEJqzcEu1ZcX4NlopuJfPtxr8P3L52-br-j65mq7-XiNHOd9RVxyJYzEPempwrQNLX0vjCADEY46a7uuJ-MgLZWO2RNLTTd01mJpTwBbgw_n3P1iZz-49olsJr3PYTb5qJMJ-l8mhlu9SwcthJCCshbw5iEgp5-LL1XPoTg_TSb6tBRNueiwYqqteg3oWepyKiX78fEZgvWpMH0uTLfC9O_C9LGZXv894KPlT0NNwM6C0qi481nfpSW3bZb_xf4CXJOjXw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2475093917</pqid></control><display><type>article</type><title>Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes</title><source>Springer Nature</source><creator>Kaur, Harpinder ; Shekhar, Nishant ; Sharma, Saurabh ; Sarma, Phulen ; Prakash, Ajay ; Medhi, Bikash</creator><creatorcontrib>Kaur, Harpinder ; Shekhar, Nishant ; Sharma, Saurabh ; Sarma, Phulen ; Prakash, Ajay ; Medhi, Bikash</creatorcontrib><description>Introduction
COVID-19 cases are on surge; however, there is no efficient treatment or vaccine that can be used for its management. Numerous clinical trials are being reviewed for use of different drugs, biologics, and vaccines in COVID-19. A much empirical approach will be to repurpose existing drugs for which pharmacokinetic and safety data are available, because this will facilitate the process of drug development. The article discusses the evidence available for the use of Ivermectin, an anti-parasitic drug with antiviral properties, in COVID-19.
Methods
A rational review of the drugs was carried out utilizing their clinically significant attributes. A more thorough understanding was met by virtual embodiment of the drug structure and realizable viral targets using artificial intelligence (AI)-based and molecular dynamics (MD)-simulation-based study.
Conclusion
Certain studies have highlighted the significance of ivermectin in COVID-19; however, it requires evidences from more Randomised Controlled Trials (RCTs) and dose- response studies to support its use. In silico-based analysis of ivermectin’s molecular interaction specificity using AI and classical mechanics simulation-based methods indicates positive interaction of ivermectin with viral protein targets, which is leading for SARS-CoV 2 N-protein NTD (nucleocapsid protein N-terminal domain).</description><identifier>ISSN: 1734-1140</identifier><identifier>EISSN: 2299-5684</identifier><identifier>DOI: 10.1007/s43440-020-00195-y</identifier><identifier>PMID: 33389725</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Drug Safety and Pharmacovigilance ; Medicine ; Pharmacotherapy ; Pharmacy ; Review</subject><ispartof>Pharmacological reports, 2021-06, Vol.73 (3), p.736-749</ispartof><rights>Maj Institute of Pharmacology Polish Academy of Sciences 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-48497a8061629023898e67a71d17c2cbb5561fd8b28c3b898e2a5d5bb08bc3b83</citedby><cites>FETCH-LOGICAL-c446t-48497a8061629023898e67a71d17c2cbb5561fd8b28c3b898e2a5d5bb08bc3b83</cites><orcidid>0000-0002-4017-641X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33389725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaur, Harpinder</creatorcontrib><creatorcontrib>Shekhar, Nishant</creatorcontrib><creatorcontrib>Sharma, Saurabh</creatorcontrib><creatorcontrib>Sarma, Phulen</creatorcontrib><creatorcontrib>Prakash, Ajay</creatorcontrib><creatorcontrib>Medhi, Bikash</creatorcontrib><title>Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes</title><title>Pharmacological reports</title><addtitle>Pharmacol. Rep</addtitle><addtitle>Pharmacol Rep</addtitle><description>Introduction
COVID-19 cases are on surge; however, there is no efficient treatment or vaccine that can be used for its management. Numerous clinical trials are being reviewed for use of different drugs, biologics, and vaccines in COVID-19. A much empirical approach will be to repurpose existing drugs for which pharmacokinetic and safety data are available, because this will facilitate the process of drug development. The article discusses the evidence available for the use of Ivermectin, an anti-parasitic drug with antiviral properties, in COVID-19.
Methods
A rational review of the drugs was carried out utilizing their clinically significant attributes. A more thorough understanding was met by virtual embodiment of the drug structure and realizable viral targets using artificial intelligence (AI)-based and molecular dynamics (MD)-simulation-based study.
Conclusion
Certain studies have highlighted the significance of ivermectin in COVID-19; however, it requires evidences from more Randomised Controlled Trials (RCTs) and dose- response studies to support its use. In silico-based analysis of ivermectin’s molecular interaction specificity using AI and classical mechanics simulation-based methods indicates positive interaction of ivermectin with viral protein targets, which is leading for SARS-CoV 2 N-protein NTD (nucleocapsid protein N-terminal domain).</description><subject>Drug Safety and Pharmacovigilance</subject><subject>Medicine</subject><subject>Pharmacotherapy</subject><subject>Pharmacy</subject><subject>Review</subject><issn>1734-1140</issn><issn>2299-5684</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9UU2PEyEYJkbjdqt_wIPh6AXlawbwYGKqrk022Yt6JcAwXTYzUIHppv9eateNXjwQkueLl_cB4BXBbwnG4l3hjHOMMG0HE9Wh4xOwolQp1PWSPwUrIhhHhHB8AS5LucOYE8q65-CCMSaVoN0KHLYHn2fvaojQFGjgPlUfazATHPKyg2PKsGZv6txQmEa4ufmx_YSIeg9NhCGicowOZn8I_h7eh3oL3RRicM1v4gBdmvdLNTWkeEJqzcEu1ZcX4NlopuJfPtxr8P3L52-br-j65mq7-XiNHOd9RVxyJYzEPempwrQNLX0vjCADEY46a7uuJ-MgLZWO2RNLTTd01mJpTwBbgw_n3P1iZz-49olsJr3PYTb5qJMJ-l8mhlu9SwcthJCCshbw5iEgp5-LL1XPoTg_TSb6tBRNueiwYqqteg3oWepyKiX78fEZgvWpMH0uTLfC9O_C9LGZXv894KPlT0NNwM6C0qi481nfpSW3bZb_xf4CXJOjXw</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Kaur, Harpinder</creator><creator>Shekhar, Nishant</creator><creator>Sharma, Saurabh</creator><creator>Sarma, Phulen</creator><creator>Prakash, Ajay</creator><creator>Medhi, Bikash</creator><general>Springer International Publishing</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4017-641X</orcidid></search><sort><creationdate>20210601</creationdate><title>Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes</title><author>Kaur, Harpinder ; Shekhar, Nishant ; Sharma, Saurabh ; Sarma, Phulen ; Prakash, Ajay ; Medhi, Bikash</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-48497a8061629023898e67a71d17c2cbb5561fd8b28c3b898e2a5d5bb08bc3b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Drug Safety and Pharmacovigilance</topic><topic>Medicine</topic><topic>Pharmacotherapy</topic><topic>Pharmacy</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaur, Harpinder</creatorcontrib><creatorcontrib>Shekhar, Nishant</creatorcontrib><creatorcontrib>Sharma, Saurabh</creatorcontrib><creatorcontrib>Sarma, Phulen</creatorcontrib><creatorcontrib>Prakash, Ajay</creatorcontrib><creatorcontrib>Medhi, Bikash</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacological reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaur, Harpinder</au><au>Shekhar, Nishant</au><au>Sharma, Saurabh</au><au>Sarma, Phulen</au><au>Prakash, Ajay</au><au>Medhi, Bikash</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes</atitle><jtitle>Pharmacological reports</jtitle><stitle>Pharmacol. Rep</stitle><addtitle>Pharmacol Rep</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>73</volume><issue>3</issue><spage>736</spage><epage>749</epage><pages>736-749</pages><issn>1734-1140</issn><eissn>2299-5684</eissn><abstract>Introduction
COVID-19 cases are on surge; however, there is no efficient treatment or vaccine that can be used for its management. Numerous clinical trials are being reviewed for use of different drugs, biologics, and vaccines in COVID-19. A much empirical approach will be to repurpose existing drugs for which pharmacokinetic and safety data are available, because this will facilitate the process of drug development. The article discusses the evidence available for the use of Ivermectin, an anti-parasitic drug with antiviral properties, in COVID-19.
Methods
A rational review of the drugs was carried out utilizing their clinically significant attributes. A more thorough understanding was met by virtual embodiment of the drug structure and realizable viral targets using artificial intelligence (AI)-based and molecular dynamics (MD)-simulation-based study.
Conclusion
Certain studies have highlighted the significance of ivermectin in COVID-19; however, it requires evidences from more Randomised Controlled Trials (RCTs) and dose- response studies to support its use. In silico-based analysis of ivermectin’s molecular interaction specificity using AI and classical mechanics simulation-based methods indicates positive interaction of ivermectin with viral protein targets, which is leading for SARS-CoV 2 N-protein NTD (nucleocapsid protein N-terminal domain).</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>33389725</pmid><doi>10.1007/s43440-020-00195-y</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-4017-641X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1734-1140 |
ispartof | Pharmacological reports, 2021-06, Vol.73 (3), p.736-749 |
issn | 1734-1140 2299-5684 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7778723 |
source | Springer Nature |
subjects | Drug Safety and Pharmacovigilance Medicine Pharmacotherapy Pharmacy Review |
title | Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A45%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ivermectin%20as%20a%20potential%20drug%20for%20treatment%20of%20COVID-19:%20an%20in-sync%20review%20with%20clinical%20and%20computational%20attributes&rft.jtitle=Pharmacological%20reports&rft.au=Kaur,%20Harpinder&rft.date=2021-06-01&rft.volume=73&rft.issue=3&rft.spage=736&rft.epage=749&rft.pages=736-749&rft.issn=1734-1140&rft.eissn=2299-5684&rft_id=info:doi/10.1007/s43440-020-00195-y&rft_dat=%3Cproquest_pubme%3E2475093917%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-48497a8061629023898e67a71d17c2cbb5561fd8b28c3b898e2a5d5bb08bc3b83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2475093917&rft_id=info:pmid/33389725&rfr_iscdi=true |